|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
Ƥ��Tϸ���ܰ��� |
|
��ѧ���� |
|
�������� |
| ��������������� | |
|
������ |
|
��ѧ˼ |
| PubMed | |
|
Article by |
|
Article by |
Ƥ��Tϸ���ܰ�����ϵͳҩ������
������, ��ѧ˼
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�210042
Ƥ��Tϸ���ܰ�������T�ܰ�ϸ���쳣��ֳ���ַ�Ƥ��Ϊ��Ҫ���ֵ�һ�鼲��,����ڲ�ͬ�����Ʒ�����ͬ,�С����ڻ�����ϵͳ����Ϊ�����־���ϵͳ�����еĻ�ѧ���ƺ�����������һ����,��Ҫ����һЩ�µĻ���ҩ�ϸ�����ӡ��ں϶��غ͵���¡���塣
[2] Zackheim HS,Kashani-Sabet M,Hwang ST.Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma:results in twenty-nine pationts.J Am Acad Dermatol,1996,34(4):626-631.
[3] WoUina U,Graefe T,Karte K.Treatment of relapsing or recalcitrant cu-taneous T-cell lymphoma with pegylated lipesomal doxorubicin.J Am Acad Dermatol,2000,42(1 Pt 1):40-46.
[4] Akpek G,Koh HK,Bogen S,et al.Chemotherapy with etoposide,vin-cristine,doxombicin,bolus cyclophesphamide,and oral prednisone in patients with refractory cutaneous T-cell lymphoma.Cancer,1999,86(7):1368-1376.
[5] Coors EA,von den Driesch P.Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluoeortolone therapy.Br J Dermatol,2000,143(1):127-131.
[6] Kurzroek R,Pilat S,Duvie M.Pontestatin therapy of T-cell lymphomas with cutaneous manifestations.J Clin Oncol,1999,17(10):3117-3121.
[7] Kurzrock R.Pontestatin (Nipent) in T-cell lymphomas.Semin Oncel,2000,27(2 Suppl 5):64-66.
[8] Fess FM.Activity of pentostatin (Nipont) in cutaneous T-cell lymphoma:single-agent and combination studies.Semin Oneol,2000,27(2 Suppl 5):58-63.
[9] Kuzel TM,Hurria A,Samuelson E,et al.Phase �� trial of 2-chloredeoxyadenesine for the treatment of cutaneous T-cell lymphoma.Blood,1996,87(3):906-911.
[10] Zinzani PL,Baliva G,Magagnoli M,et al.Gemcitabine treatment in pre-treated cutaneous T-cell lymphoma:experience in 44 patients.J Clin On-col,2000,18(13):2603-2606.
[11] Siegel KS,Pandolfino T,Guitart J,et al.Primary cutaneous T-cell lym-phoma:review and current eoncepts.J Clin Oncol,2000,18(15):2908-2925.
[12] Hanney JE.From the Food and Drag Administration.JAMA,2000,283(9):1131.
[13] Jumbou O,N' Guyen JM,Tessier MH,et al.I-ong-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interfemn-alfa.Br J Dermatol,1999,140(3):427-431.
[14] Rook All,Wood GS,Yon EK,et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood,1999,94(3):902-908.
[15] Marolleau JP,Baccard M,Flageul B,et al.High-dose recombinant inter-leukin-2 in advanced cutaneous T-cell lymphoma.Arch Dermatol,1995,131(5):574-579.
[16] LeMaistre CF,Saleh MN,Kuzel TM,et al.Phase I trial of a ligand fu-sion-protein (DAB3891L-2) in lymphomas expressing the receptor for in-terleukin-2.Blood,1998,91 (2):399-405.
[17] Saleh MN,IeMaistre CF,Kuzel TM,et al.Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.J Am Acad Dennatol,1998,39(1):63-73.
[18] Olsen E,Duvie M,Frankel A,et al.Pivotal phase �� trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lym-phoma.J Clin Oncol,2001,19 (2):376-388.
[19] Knox S,Hoppe RT,Maloney D,et al.Treatment of cutaneous T-cell lym-phoma with chimeric onti-CD4 monoclonal antibody.Blood,1996,87 (3):893-899.
[20] Pawson R,Dyer MJ,Barge R,et al.Treatment of T-ceil prolymphocytic leukemia with human CD52 antibedy.J Clin Oncol,1997,15(7):2667-2672.
[21] Lundin J,Osterborg A,Brittinger G,et al.CAMPATH-1H monoclonal an-tibody in therapy for previously treated low-grade non-Hedgkin's lym-phomas:a phase �� multieenter study.European Study Group of CAM-PATH-1H Treatment in Low-Grade Non-Hedgkin's Lymphoma.J Clin On-col,1998,16(10):3257-3263.